Journal:

Article Title: Regulation of Bovine Leukemia Virus tax and pol mRNA Levels by Interleukin-2 and -10

doi:

Figure Lengend Snippet: IL-2 and ConA stimulate BLV tax and pol mRNA levels. PBMCs from the PL animal P191 were cultured with recombinant human IL-2 (100 U/ml) or ConA (10 μg/ml) for 5 days. QC-PCR was performed (A), and the amounts of BLV tax and pol mRNA are shown (B), with standard error bars from at least three assays, and the data are representative of experiments with three different animals. The bands are as follows: 691 bp, tax standard; 450 bp, tax mimic; 700 bp pol mimic; 530 bp pol standard; and 890 bp, β-actin. All products were analyzed on a 1% agarose gel stained with ethidium bromide.

Article Snippet: The cells were treated with human recombinant IL-2 (hrIL-2; 100 U/ml; PharMingen, San Diego, Calif.), hrIL-10 (10 ng/ml; R&D systems, Minneapolis, Minn.), hrIL-12 (5 ng/ml; R&D systems), anti-hrIL10 neutralizing antibody (10 μg/ml; R&D systems), concanavalin A (ConA; 10 μg/ml; Sigma, St. Louis, Mo.), and BLV (10 μg/ml).

Techniques: Cell Culture, Recombinant, Agarose Gel Electrophoresis, Staining

Journal:

Article Title: Regulation of Bovine Leukemia Virus tax and pol mRNA Levels by Interleukin-2 and -10

doi:

Figure Lengend Snippet: IL-2 and ConA stimulate BLV p24 protein production. PBMCs from PL animal P49 were cultured with hrIL-2 (100 U/ml) or ConA (10 μg/ml) for 3 days. After protein purification, an equal amount of protein from each sample was analyzed by SDS–10% PAGE. (A) Immunoblotting was performed with mouse anti-BLV p24 antibody and alkaline phosphatase-conjugated goat anti-mouse IgG antibody. (B) Each band was analyzed by densitometry by using the NIH Image program version 1.61 to measure relative band density. Purified BLV was used as a positive control. The data are representative data of experiments with two different PL animals. Standard error bars are shown from at least four separate experiments.

Article Snippet: The cells were treated with human recombinant IL-2 (hrIL-2; 100 U/ml; PharMingen, San Diego, Calif.), hrIL-10 (10 ng/ml; R&D systems, Minneapolis, Minn.), hrIL-12 (5 ng/ml; R&D systems), anti-hrIL10 neutralizing antibody (10 μg/ml; R&D systems), concanavalin A (ConA; 10 μg/ml; Sigma, St. Louis, Mo.), and BLV (10 μg/ml).

Techniques: Cell Culture, Protein Purification, Western Blot, Purification, Positive Control